Abbonarsi

Hexaminolevulinate-induced fluorescence endoscopy in patients with rectal adenoma and cancer: a pilot study - 24/08/11

Doi : 10.1016/S0016-5107(04)01723-7 
Esther Endlicher, MD ⁎, Cornelia M. Gelbmann, MD, Ruth Knüchel, MD, Alois Fürst, MD, Rolf M. Szeimies, MD, Stefan K. Gölder, MD, Jürgen Schölmerich, MD, Christian Lottner, PhD, Helmut Messmann, MD
Current affiliations: Department of Internal Medicine I, Department of Surgery, Department of Dermatology, Institute of Pathology, University of Regensburg, Regensburg, Germany, Institute of Pathology, University of Aachen, Aachen, Germany, Department of Internal Medicine III, Klinikum Augsburg, Germany 

Reprint requests: E. Endlicher, MD, Department of Internal Medicine 1, University of Regensburg, 93042 Regensburg, Germany.

Abstract

Background

Fluorescence endoscopy is a promising new method for detection and treatment of premalignant and malignant lesions. The aim of this pilot study was to investigate the feasibility of hexaminolevulinate-based photodetection of rectal adenoma and cancer, including safety, dose finding, and efficacy.

Methods

Ten patients with known rectal adenoma or cancer were sensitized by instillation of 3.2 mM of hexaminolevulinate as an enema. Fluorescence endoscopy was performed after retention of the enema for 30 to 60 minutes, followed by a rest time of up to 30 minutes before endoscopy. Biopsy specimens were taken from fluorescent and non-fluorescent areas and fluorescence microscopy studies were performed to assess the distribution of protoporphyrin IX fluorescence in different tissue layers. Adverse events were reported by direct questioning of all patients; skin photosensitivity, changes in biochemical tests of liver function, blood pressure and heart rate, and the occurrence of GI symptoms (nausea, vomiting) were recorded for 5 patients.

Observations

Hexaminolevulinate-induced fluorescence endoscopy produced selective fluorescence of all rectal adenomas with intraepithelial neoplasia. For rectal cancer, there was only weak fluorescence or none at all. No hexaminolevulinate-induced side effect was observed. In two patients, fluorescence differentiated adenomas and hyperplastic polyps.

Conclusions

Hexaminolevulinate-based fluorescence endoscopy (3.2 mM administered as an enema) in patients with rectal cancer and adenoma was well tolerated and produced no significant skin sensitivity or other side effects. The optimal duration of application is 30 to 45 minutes, with a rest time of 30 minutes. Selective fluorescence of adenoma with intraepithelial neoplasia suggests that hexaminolevulinate-based fluorescence endoscopy may be useful for detection of premalignant lesions.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2004  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 60 - N° 3

P. 449-454 - settembre 2004 Ritorno al numero
Articolo precedente Articolo precedente
  • The elective evaluation of patients with suspected choledocholithiasis undergoing laparoscopic cholecystectomy
  • Frances Tse, Jeffrey S. Barkun, Alan N. Barkun
| Articolo seguente Articolo seguente
  • Extracorporeal shockwave lithotripsy of gallstones in cystic duct remnants and Mirizzi syndrome
  • Johannes Benninger, Thomas Rabenstein, Michael Farnbacher, Jens Keppler, Eckhart G. Hahn, H.Thomas Schneider

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.